These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

829 related articles for article (PubMed ID: 25730880)

  • 1. Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK.
    Sagiv-Barfi I; Kohrt HE; Czerwinski DK; Ng PP; Chang BY; Levy R
    Proc Natl Acad Sci U S A; 2015 Mar; 112(9):E966-72. PubMed ID: 25730880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bruton's tyrosine kinase (BTK) as a promising target in solid tumors.
    Molina-Cerrillo J; Alonso-Gordoa T; Gajate P; Grande E
    Cancer Treat Rev; 2017 Jul; 58():41-50. PubMed ID: 28641100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes.
    Dubovsky JA; Beckwith KA; Natarajan G; Woyach JA; Jaglowski S; Zhong Y; Hessler JD; Liu TM; Chang BY; Larkin KM; Stefanovski MR; Chappell DL; Frissora FW; Smith LL; Smucker KA; Flynn JM; Jones JA; Andritsos LA; Maddocks K; Lehman AM; Furman R; Sharman J; Mishra A; Caligiuri MA; Satoskar AR; Buggy JJ; Muthusamy N; Johnson AJ; Byrd JC
    Blood; 2013 Oct; 122(15):2539-49. PubMed ID: 23886836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myeloid-Derived Suppressor Cells Express Bruton's Tyrosine Kinase and Can Be Depleted in Tumor-Bearing Hosts by Ibrutinib Treatment.
    Stiff A; Trikha P; Wesolowski R; Kendra K; Hsu V; Uppati S; McMichael E; Duggan M; Campbell A; Keller K; Landi I; Zhong Y; Dubovsky J; Howard JH; Yu L; Harrington B; Old M; Reiff S; Mace T; Tridandapani S; Muthusamy N; Caligiuri MA; Byrd JC; Carson WE
    Cancer Res; 2016 Apr; 76(8):2125-36. PubMed ID: 26880800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Irreversible dual inhibitory mode: the novel Btk inhibitor PLS-123 demonstrates promising anti-tumor activity in human B-cell lymphoma.
    Ding N; Li X; Shi Y; Ping L; Wu L; Fu K; Feng L; Zheng X; Song Y; Pan Z; Zhu J
    Oncotarget; 2015 Jun; 6(17):15122-36. PubMed ID: 25944695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bruton's Tyrosine Kinase Inhibitors Prevent Therapeutic Escape in Breast Cancer Cells.
    Wang X; Wong J; Sevinsky CJ; Kokabee L; Khan F; Sun Y; Conklin DS
    Mol Cancer Ther; 2016 Sep; 15(9):2198-208. PubMed ID: 27256378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of ibrutinib on inflammation in a mouse model of Graves' orbitopathy.
    Kim C; Park JH; Choi YJ; Jun HO; Chung JK; Park TK; Yoon JS; Yang JW; Jang SY
    Front Endocrinol (Lausanne); 2024; 15():1420024. PubMed ID: 39280007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ibrutinib inhibits pre-BCR
    Kim E; Hurtz C; Koehrer S; Wang Z; Balasubramanian S; Chang BY; Müschen M; Davis RE; Burger JA
    Blood; 2017 Mar; 129(9):1155-1165. PubMed ID: 28031181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Bruton's tyrosine kinase inhibitor ibrutinib exerts immunomodulatory effects through regulation of tumor-infiltrating macrophages.
    Ping L; Ding N; Shi Y; Feng L; Li J; Liu Y; Lin Y; Shi C; Wang X; Pan Z; Song Y; Zhu J
    Oncotarget; 2017 Jun; 8(24):39218-39229. PubMed ID: 28424405
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors.
    Hong D; Rasco D; Veeder M; Luke JJ; Chandler J; Balmanoukian A; George TJ; Munster P; Berlin JD; Gutierrez M; Mita A; Wakelee H; Samakoglu S; Guan S; Dimery I; Graef T; Borazanci E
    Oncology; 2019; 97(2):102-111. PubMed ID: 31230047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of Bruton's tyrosine kinase and IL-2 inducible T-cell kinase suppresses both neutrophilic and eosinophilic airway inflammation in a cockroach allergen extract-induced mixed granulocytic mouse model of asthma using preventative and therapeutic strategy.
    Nadeem A; Ahmad SF; Al-Harbi NO; Ibrahim KE; Siddiqui N; Al-Harbi MM; Attia SM; Bakheet SA
    Pharmacol Res; 2019 Oct; 148():104441. PubMed ID: 31505252
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ibrutinib (ImbruvicaTM) potently inhibits ErbB receptor phosphorylation and cell viability of ErbB2-positive breast cancer cells.
    Grabinski N; Ewald F
    Invest New Drugs; 2014 Dec; 32(6):1096-104. PubMed ID: 25081321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma.
    Ruella M; Kenderian SS; Shestova O; Fraietta JA; Qayyum S; Zhang Q; Maus MV; Liu X; Nunez-Cruz S; Klichinsky M; Kawalekar OU; Milone M; Lacey SF; Mato A; Schuster SJ; Kalos M; June CH; Gill S; Wasik MA
    Clin Cancer Res; 2016 Jun; 22(11):2684-96. PubMed ID: 26819453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The BTK Inhibitor Ibrutinib (PCI-32765) Overcomes Paclitaxel Resistance in ABCB1- and ABCC10-Overexpressing Cells and Tumors.
    Zhang H; Patel A; Wang YJ; Zhang YK; Kathawala RJ; Qiu LH; Patel BA; Huang LH; Shukla S; Yang DH; Ambudkar SV; Fu LW; Chen ZS
    Mol Cancer Ther; 2017 Jun; 16(6):1021-1030. PubMed ID: 28265007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ibrutinib Inhibits ERBB Receptor Tyrosine Kinases and HER2-Amplified Breast Cancer Cell Growth.
    Chen J; Kinoshita T; Sukbuntherng J; Chang BY; Elias L
    Mol Cancer Ther; 2016 Dec; 15(12):2835-2844. PubMed ID: 27678331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by Ibrutinib induces apoptosis.
    Cinar M; Hamedani F; Mo Z; Cinar B; Amin HM; Alkan S
    Leuk Res; 2013 Oct; 37(10):1271-7. PubMed ID: 23962569
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ibrutinib.
    Charalambous A; Schwarzbich MA; Witzens-Harig M
    Recent Results Cancer Res; 2018; 212():133-168. PubMed ID: 30069629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combining ibrutinib and checkpoint blockade improves CD8+ T-cell function and control of chronic lymphocytic leukemia in Em-TCL1 mice.
    Hanna BS; Yazdanparast H; Demerdash Y; Roessner PM; Schulz R; Lichter P; Stilgenbauer S; Seiffert M
    Haematologica; 2021 Apr; 106(4):968-977. PubMed ID: 32139435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ibrutinib synergizes with poly(ADP-ribose) glycohydrolase inhibitors to induce cell death in AML cells via a BTK-independent mechanism.
    Rotin LE; Gronda M; MacLean N; Hurren R; Wang X; Lin FH; Wrana J; Datti A; Barber DL; Minden MD; Slassi M; Schimmer AD
    Oncotarget; 2016 Jan; 7(3):2765-79. PubMed ID: 26624983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) blocks hairy cell leukaemia survival, proliferation and B cell receptor signalling: a new therapeutic approach.
    Sivina M; Kreitman RJ; Arons E; Ravandi F; Burger JA
    Br J Haematol; 2014 Jul; 166(2):177-88. PubMed ID: 24697238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.